Home » FDA Gives Go Ahead to Eli Lilly’s Alzheimer’s Diagnostic Amyvid
FDA Gives Go Ahead to Eli Lilly’s Alzheimer’s Diagnostic Amyvid
The FDA approved Eli Lilly’s radioactive diagnostic for detection of the tell-tale sign of Alzheimer’s disease, setting the stage for its pairing with experimental treatments for the condition now in late-stage development. Amyvid (florbetapir F 18 injection) binds to beta-amyloid plaques in patients’ brains. The plaques — detected using positron emission tomography, or PET scans — are believed to cause Alzheimer’s.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May